Literature DB >> 23141876

Non-alcoholic fatty liver disease and cardiovascular risk.

Angel Brea1, José Puzo.   

Abstract

The term "Non-alcoholic fatty liver disease" (NAFLD) covers a series of liver lesions similar to those induced by alcohol, but not caused by alcohol use. The importance of NAFLD lies in the high prevalence in Western societies and, from the point of view of the liver, in its progression from steatosis to cirrhosis and liver cancer. More recently, NAFLD has been found to be associated with lipid metabolism disorders, the deposition of fat outside of the adipocytes, insulin resistance and Metabolic Syndrome. Also attributed to NAFLD is a heightened systemic pro-inflammatory state, which accelerates arteriosclerosis, thereby increasing cardiovascular risk and associated cardiovascular events. Here we provide an update to the etiopathogenesis of NAFLD, its influence on cardiovascular disease, and the treatment options.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alcohol; Cardiovascular disease; Fatty liver; Non-alcoholic fatty liver disease

Mesh:

Year:  2012        PMID: 23141876     DOI: 10.1016/j.ijcard.2012.09.085

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  24 in total

1.  Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease.

Authors:  Seung Hwan Moon; Sun-Pyo Hong; Young Seok Cho; Tae Soo Noh; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  J Nucl Cardiol       Date:  2015-10-28       Impact factor: 5.952

2.  Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease.

Authors:  Xia Cao; Jiansong Zhou; Hong Yuan; Zhiheng Chen
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

Review 3.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

4.  Non-alcoholic steatohepatitis aggravates nitric oxide synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rat model.

Authors:  Shogo Watanabe; Shota Kumazaki; Shusei Yamamoto; Ikumi Sato; Kazuya Kitamori; Mari Mori; Yukio Yamori; Satoshi Hirohata
Journal:  Int J Exp Pathol       Date:  2019-01-24       Impact factor: 1.925

Review 5.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study.

Authors:  Panu Rantakokko; Ville Männistö; Riikka Airaksinen; Jani Koponen; Matti Viluksela; Hannu Kiviranta; Jussi Pihlajamäki
Journal:  Environ Health       Date:  2015-09-29       Impact factor: 5.984

7.  The VASP Road to NAFLD: A Macrophage Detour.

Authors:  Guido Lastra; Camila Manrique; Guanghong Jia; James R Sowers
Journal:  Diabetes       Date:  2015-08       Impact factor: 9.461

Review 8.  Obesity: physiologic changes and implications for preoperative management.

Authors:  Vilma E Ortiz; Jean Kwo
Journal:  BMC Anesthesiol       Date:  2015-07-04       Impact factor: 2.217

9.  Nonalcoholic Fatty Liver Disease is Associated with Increased Carotid Intima-Media Thickness in Type 1 Diabetic Patients.

Authors:  Lei Zhang; Kaifeng Guo; Junxi Lu; Fangya Zhao; Haoyong Yu; Junfeng Han; Yuqian Bao; Haibing Chen; Weiping Jia
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

10.  The AST/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients.

Authors:  Peter Rief; Martin Pichler; Reinhard Raggam; Franz Hafner; Armin Gerger; Philipp Eller; Marianne Brodmann; Thomas Gary
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.